Case Study: When Standard Genomic Interpretation Found Nothing, Genoxus Found More

Re-analyze your genetic data with Genoxus!

Beyond the Initial Report: New Genetic Signals Identified

A genetic diagnostic and research organization submitted a Whole Exome Sequencing (WES) VCF file to Genoxus for independent reanalysis. In short, the original genomic interpretation found nothing related to the patient’s disease. The original report concluded that no pathogenic or likely pathogenic variants that could explain the phenotype were found.
Using the Genoxus analysis platform and engine, additional phenotype-associated variants linked to dwarfism, macrocephaly, hydrocephalus, and cardiovascular features were identified — prompting further segregation interest.

Reaction From Genetic Company-X

After reviewing the Genoxus findings, Dr. A, PhD, researcher and CEO from the submitting genetic organization (Company-X), described the results as:
“A very good finding.”
“These variants are very closely linked with the phenotype.”
“I am interested in a segregation study to verify these variants.”

The Original Clinical Interpretation

Before Genoxus Re-analysis

The original Whole Exome Sequencing (WES) interpretation reported:
  • No pathogenic or likely pathogenic variants explain the primary phenotype
  • Achondroplasia-like presentation in two affected siblings
  • Secondary TTN-related cardiomyopathy finding
  • No additional clinically relevant findings were identified

What Genoxus Discovered

Genoxus Reanalysis Revealed Additional Phenotype-Associated Variants

Using advanced genomic annotation, phenotype correlation, and variant prioritization workflows, Genoxus identified multiple variants associated with the prominent features of achondroplasia.
  • NM_016648.4(LARP7):c.651G>C (p.Glu217Asp)
  • NM_001159773.2(CANT1):c.*89G>A
  • NM_001374353.1(GLI2):c.4507G>A (p.Asp1503Asn)
  • NM_024301.5(FKRP):c.249C>T (p.Ala83=)

Why This Matters?

Whole Exome and Whole Genome (WES/WGS) raw datasets can contain thousands of variants. Traditional reporting pipelines may prioritize only a narrow subset of findings. Genoxus focuses on deeper phenotype-driven reanalysis by combining:
  • Variant annotation
  • Multi-database cross-referencing
  • Clinical phenotype correlation
  • Literature-supported associations
  • Expanded interpretation workflows
The result is a broader layer of genomic insight that may support:
  • Further investigation
  • Research validation
  • Segregation analysis
  • Hypothesis generation
  • Clinical collaboration

Have WGS/WES Dataset That Needs Deeper Review?

If you already have a WGS/WES VCF raw data file and are interested in having Genoxus perform a re-analysis, please let us know. We are looking to collaborate with patients, researchers, clinicians, genetic diagnostic laboratories, hospitals, universities, and biotech organizations seeking deeper genomic insight beyond standard interpretation workflows.
Whether you are exploring unresolved cases, phenotype-driven analysis, variant prioritization, segregation studies, or independent secondary review, Genoxus is open to research collaborations, technical demonstrations, and case study partnerships.
Disclaimer: Genoxus materials, reports, analyses, and platform outputs are provided for research, educational, and informational purposes only. They are not intended to serve as clinical, diagnostic, or medical advice and have not been validated or approved for use in medical decision-making. Any insights or interpretations generated by Genoxus are exploratory in nature and are intended to support research, evaluation, and collaborative learning. These materials should not be used as the sole basis for diagnosis, treatment, patient management, or healthcare decisions. All medical or clinical decisions should be made in consultation with qualified healthcare professionals and supported by appropriately validated clinical testing.

Join Us on the Journey

We collaborate with clinicians, researchers, healthcare organizations, and strategic partners who share our commitment to advancing precision medicine.